Weekly Recap: GE Healthcare launches AI tools and UBS raises target
GE Healthcare (GEHC) launched AI tools for its Vscan Air handheld ultrasound, available in the U.S. and select markets. UBS raised its price target on GEHC to $80 from $73, maintaining a Neutral rating. Chief Science and Technology Officer Taha Kass-Hout will resign in December 2026.
How this was made

The 30-second read
Why it matters
The announcement could drive short‑term buying pressure and longer‑term revenue growth expectations.
Market read
Fresh product launch and analyst upgrade provide a modest catalyst for GEHC.
What to watch
Potential regulatory scrutiny in other regions and the impact of the CTO departure on execution.
Background
GE Healthcare is expanding its handheld ultrasound portfolio with AI capabilities, a trend across the diagnostics industry.
Ticker impact
GE Healthcare announced FDA‑cleared AI tools for its Vscan Air ultrasound and disclosed a CTO resignation, plus UBS raised its price target to $80.
modest upside as investors price in the AI tool rollout and higher target
First‑report product launch with regulatory clearance and an analyst target increase are fresh, material news for a mid‑cap medical‑technology company.
Market effects
May boost sentiment for medical‑device and AI‑enabled imaging firms.
U.S. healthcare equipment market could see slight uplift.
Limited to investors tracking AI integration in diagnostics.
Counterpoint
The AI tools may face adoption hurdles and competition, limiting upside.
Key entities
- companyGE Healthcare Technologies Inc.
U.S. listed medical‑device maker launching AI tools.
- analystUBS
Raised GEHC price target to $80.

